R. Kanthan et al., Gallbladder carcinomas: An immunoprognostic evaluation of P53, Bcl-2, CEA and alpha-fetoprotein, CAN J GASTR, 14(3), 2000, pp. 181-184
The p53 gene is the most frequently mutated gene in many human cancers, inc
luding those of the colon, breast, lung, esophagus, liver and brain. Such g
enetically mutated rumours are generally associated with progression of the
disease and poor clinical outcome. One hundred cases of documented gallbla
dder carcinomas were reviewed. Twenty-eight cases were randomly selected to
evaluate the expression of P53, Bcl-2, carcinoembryonic antigen (CEA) and
alpha-fetoprotein, in both the in situ (19 cases) and invasive components (
28 cases) of the tumour by the avidin-biotin complex method of immunohistoc
hemistry. These results were correlated with the mean survival intervals in
an effort to clarify the progression of the disease and evaluate their rol
e as prognostic markers. Staining to alpha-fetoprotein and Bcl-2 remained c
onsistently negative to weak insignificant staining in both the in situ and
invasive components of the tumour in all cases. P53 staining of the invasi
ve part of the tumour was seen in 24 (86%) of the cases and in 17 (89%) of
the in situ component. The in situ staining patterns of P53 were not statis
tically significant in relation to the mean survival. However, in the invas
ive component, moderate to strong staining rumours, as seen in 15 (54%) cas
es, were associated with a mean survival of 8.8 months. A similar trend was
also observed with staining patterns to CEA. Eighty-nine per cent of the i
nvasive and 84% of the in situ components of the tumour stained positive to
CEA. Moderate to strong staining of both the in situ and the invasive comp
onents of the rumours was associated with a mean survival of 10.6 months in
76% of cases.
This study shows that altered expressions of P53 and CEA are detectable by
immunohistochemistry in gallbladder carcinomas. Tumours with increased expr
ession of P53 and CEA of a strong to moderate staining were associated with
Door clinical outcomes as evidenced by their mean survival. A stepwise pro
gression of altered CEA and P53 expression may reflect ongoing progression
of the disease hom the in situ to the invasive phase. However, such trends
need to be evaluated in larger numbers and are thus not considered to be tr
ue independent prognostic markers.